Holen Sie sich die Stockscreener-App
1.06
0.96%
0.02
Schlusskurs vom Vortag:
$1.04
Offen:
$1.03
24-Stunden-Volumen:
295.81K
Relative Volume:
1.46
Marktkapitalisierung:
$26.38M
Einnahmen:
$522.00K
Nettoeinkommen (Verlust:
$-10.80M
KGV:
-1.8454
EPS:
-0.5744
Netto-Cashflow:
$-8.78M
1W Leistung:
+34.62%
1M Leistung:
+26.69%
6M Leistung:
+25.00%
1J Leistung:
-25.53%
1-Tages-Spanne:
$0.9614
$1.06
1-Wochen-Bereich:
$0.7701
$1.06
52-Wochen-Spanne:
$0.46
$1.69
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.06 | 25.88M | 522.00K | -10.80M | -8.78M | -0.5744 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria signs contract for semaglutide drug delivery study By Investing.com - Investing.com South Africa
LEXX Technical Analysis & Stock Price Forecast - Intellectia AI
Lexaria Bioscience Corp. (LEXX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Lexaria Launches New Human Trial to Advance Oral GLP-1 Drug Delivery Platform - TipRanks
Aug Retail: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocks2026 Major Catalysts & Smart Investment Allocation Tips - baoquankhu1.vn
Lexaria to Begin New Human Clinical Study in GLP-1 - Investing News Network
Lexaria signs contract for semaglutide drug delivery study - investing.com
Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders - citybuzz -
Lexaria Bioscience (LEXX) Launches Key Human Pilot Study - GuruFocus
A 5-week human trial will test Lexaria's oral GLP-1 against Wegovy - Stock Titan
Can Lexaria Bioscience Corp sustain its profitability2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Sentiment Review: What is Lexaria Bioscience Corp Equity Warrants revenue forecastDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Institution Moves: Can Lexaria Bioscience Corp lead its sector in growth - baoquankhu1.vn
History Review: What hedge funds are buying Lexaria Bioscience Corp2026 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Risk Analysis: Can Lexaria Bioscience Corp expand into new marketsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Weekly Earnings: Can Lexaria Bioscience Corp sustain its profitability2026 Action & Verified Short-Term Plans - baoquankhu1.vn
Lexaria receives 5 patents including 2 for diabetes treatment By Investing.com - Investing.com South Africa
Stock Recap: Will Lexaria Bioscience Corp Equity Warrant face regulatory challenges2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Lexaria Bolsters Global Patent Portfolio With New GLP-1 and Cardiometabolic IP - TipRanks
Lexaria's Robust Patent Portfolio Continues to Grow - Investing News Network
LEXX Advances with New Patents for Hypertension, Epilepsy, and D - GuruFocus
Lexaria receives 5 patents including 2 for diabetes treatment - Investing.com
Five new patents extend Lexaria's diabetes and epilepsy claims into 2044 - Stock Titan
FOMO Trade: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Aug Intraday: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Market Mood & Daily Entry Point Alerts - baoquankhu1.vn
Moving Averages: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEARShare Buyback & Daily Entry Point Alerts - baoquankhu1.vn
Lexaria pursues oral GLP-1 drug delivery partnerships By Investing.com - Investing.com Australia
If You Invested $1,000 in Lexaria Bioscience Corp (LEXX) - Stock Titan
Lexaria Targets Booming GLP-1 Market With Enhanced Oral Drug Platform - tipranks.com
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - Investing News Network
Lexaria pursues oral GLP-1 drug delivery partnerships - Investing.com
Lexaria Bioscience Corp.: Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - FinanzNachrichten.de
Aug Decliners: Can Lexaria Bioscience Corp expand into new markets2026 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Published on: 2026-03-22 08:08:07 - baoquankhu1.vn
Is Lexaria Bioscience Corp exposed to political risk2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
100,000 Lexaria (LEXX) shares gifted back to the company - Stock Titan
Update Recap: Is Lexaria Bioscience Corp benefiting from interest rate changesPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Volume Recap: Is Lexaria Bioscience Corp a strong candidate for buy and hold2026 Drop Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Market Rankings: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growthTrade Risk Assessment & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Lexaria launches 2026 research program for drug delivery tech - Investing.com Nigeria
Buybacks Report: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocksJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Buybacks Report: Is Lexaria Bioscience Corp Equity Warrant currently under institutional pressureAnalyst Upgrade & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Wrap: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Lexaria launches 2026 research program for drug delivery tech By Investing.com - Investing.com Australia
Lexaria Announces New R&D Plans for 2026 - Investing News Network
Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery - TipRanks
Lexaria Bioscience Corp Announces New Research and Development Program - marketscreener.com
LEXX Initiates 2026 R&D Program to Enhance Pharma Innovations - GuruFocus
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexaria Bioscience Corp-Aktie (LEXX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | Director |
Jul 30 '25 |
Buy |
0.91 |
11,900 |
10,866 |
281,912 |
| McKechnie William Edward | Director |
Jul 29 '25 |
Buy |
0.91 |
5,000 |
4,532 |
18,191 |
| DOCHERTY JOHN MARTIN | President & CSO |
Jul 29 '25 |
Buy |
0.93 |
5,376 |
4,989 |
5,376 |
| Carle Vanessa | Secretary |
Jul 29 '25 |
Buy |
0.91 |
750 |
682 |
750 |
| CHRISTOPHER RICHARD | Chief Executive Officer |
Jul 29 '25 |
Buy |
0.91 |
15,000 |
13,641 |
65,000 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):